Pacific Biomarkers continues to be on the leading edge of biomarker innovation and provides clients with the best available testing for drugs in the following areas:

- Cardiovascular
- Diabetes and Obesity
- Musculoskeletal
- Inflammation and Immunity
- Oncology
- Organ Injury

The company is CAP accredited and CLIA certified. It takes care to provide flexible, specific, project-based biomarker testing for clinical trials, rather than generic testing of biomarkers for multiple projects. Customization of each project to ensure data integrity and timely delivery is an honored principle at Pacific Biomarkers. Some ways the team enhances each client project are:

- Consultation on preanalytical issues in biomarker testing
- Making available better methods for established biomarkers
- Validation of analytically reliable novel biomarkers
- Introduction of new methods that result from collaboration with analytical teams in pharma and diagnostic fields

In addition, Pacific Biomarkers offers other specialty testing services, which include bioanalytical support for novel biotherapeutic and biosimilar product development. These services include:

- Immunogenicity testing
- Specific assay technology transfer
- Novel biomarker assay development and optimization
- Acute kidney injury biomarkers
- Multiplex testing
- HDL functionality tests

Pacific Biomarkers is the premier provider of biomarker testing services to Pharmaceutical, Biotechnology and Diagnostic industry leaders. For more than two decades the company has supported preclinical through Phase IV studies by providing pioneering biomarker testing services. As the result of integrating scientific, technical and project management activities at Pacific Biomarkers, a team of clinical trial professionals can optimize study outcomes and adhere to sponsor timelines. This team-oriented approach has assisted pharma sponsors to differentiate their products and accelerate internal decision-making.